secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2025-05-09T23:59:59+00:00
Accession:  0001437749-25-015778
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity Therapeutics Q1 net loss $2.7M, cash $27.7M; stenoparib shows durable benefit
--------------------------------------------------------------------------------

- Net loss narrowed to $2.7M in Q1 2025 from $3.8M in Q1 2024; R&D expenses $1.4M, G&A $1.6M.
- Cash and restricted cash $27.7M at March 31, 2025, up from $20.9M at December 31, 2024.
- Two ovarian cancer patients on stenoparib >19 months; new Phase 2 protocol for platinum-resistant disease begins H1 2025.
- VA-funded Phase 2 trial of stenoparib + temozolomide in SCLC to begin enrollment Q2-Q3 2025.
- Authorized $5M share repurchase program; ~2M shares bought; SEC settlement and class action lawsuit resolved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000143774925015778/0001437749-25-015778-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000143774925015778/allr20250509_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-015778

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer